---
title: "Ananda Ghosh Reiterates Buy on High-Probability NATiV3 Success and $14 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305062497.md"
description: "H.C. Wainwright analyst Ananda Ghosh reiterated a Buy rating on IVA stock with a $14 price target, citing an 85% probability of success for the NATiV3 trial. The bullish stance is based on strong Phase 2 results and favorable risk/reward dynamics. Additionally, UBS maintained a Buy rating with a $12 price target on November 1."
datetime: "2026-11-10T20:25:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305062497.md)
  - [en](https://longbridge.com/en/news/305062497.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305062497.md)
generator: "portal-rs"
---

# Ananda Ghosh Reiterates Buy on High-Probability NATiV3 Success and $14 Price Target

H.C. Wainwright analyst Ananda Ghosh has maintained their bullish stance on IVA stock, giving a Buy rating on November 1.

Ananda Ghosh’s rating is based on several factors, including an expert hepatologist’s view that lanifibranor could stand out if it produces a roughly 19–20-point placebo-adjusted fibrosis improvement in MASH. Ghosh expects NATiV3 to meet its primary endpoint, assigning about an 85% success probability and 78% for success on both the composite and fibrosis measures. Those expectations are supported by lanifibranor’s strong Phase 2 results and the larger Phase 3 study’s ability to achieve significance with a smaller effect.  
He also sees a commercial role for an oral, insulin-sensitizing antifibrotic used alongside incretin therapies, with Rezdiffra the more relevant competitor; differentiation could support adoption among F3 patients and injection-averse or diabetic patients. Scenario analysis indicates substantial upside, while the shares’ roughly $0.84 billion valuation creates an asymmetric risk/reward profile despite safety, placebo-response, payer, and competitive risks. The price target remains unchanged at $14, reinforcing the Buy recommendation ahead of the readout.

In another report released on November 1, UBS also maintained a Buy rating on the stock with a $12.00 price target.

### Related Stocks

- [IVA.US](https://longbridge.com/en/quote/IVA.US.md)
- [UBS.US](https://longbridge.com/en/quote/UBS.US.md)

## Related News & Research

- [Inventiva Publishes Presentation on Lanifibranor's Antifibrotic Effects in Preclinical Models](https://longbridge.com/en/news/305136113.md)
- [J.P. Morgan Raises Inventiva Voting Rights to 5.21%](https://longbridge.com/en/news/305310429.md)
- [Nasdaq (NDAQ) Just Gave Investors Something To Think About](https://longbridge.com/en/news/306370324.md)
- [Anthropic PBC (ANT) Claims Claude Solved The 167 Year Old Riemann Hypothesis](https://longbridge.com/en/news/306374461.md)
- [How New LNG Cruise Ships At Carnival (CCL) Has Changed Its Investment Story](https://longbridge.com/en/news/306370478.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**